SAB Biotherapeutics (SABS) Debt Ratio (2020 - 2022)

SAB Biotherapeutics' (SABS) quarterly Debt Ratio came in at 0.01 in Q4 2022, up 249.68% on a QoQ basis from 0.0 in Q4 2020.

SAB Biotherapeutics (SABS) Debt Ratio (2020 - 2022) Analysis & Trends

SAB Biotherapeutics (SABS) has 2 years of Debt Ratio data on file, last reported at 0.01 in Q4 2022.

Quarterly Debt Ratio changed N/A year-over-year to 0.01 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 0.01 (changed N/A YoY) and the FY2022 annual result came in at 0.01, changed N/A from the prior year.
Debt Ratio climbed to 0.01 in Q4 2022, from 0.0 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.01 in Q4 2022 to a low of 0.0 in Q4 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	SAB Biotherapeutics	308.92 Mn	308.92 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2022	0.01
Dec 31, 2020	0.00